No differences in hemostatic and endothelial activations between haploidentical and matched-donor hematopoietic stem cell transplantation in thalassemia disease

Table 1 Demographic data for Thal-HSCT patients by donor group: haploidentical and matched-donor

	Type of donor		P-value
	Haploidentical n = 14	Matched-donor n = 9	P-value
Type of thalassemia, n (%)			0.295^a
HbE/β	13 (93)	7 (78)
β major	1 (7)	2 (22)
Age at HSCT in years, median (range)	10.6 (2.7–18.9)	8.2 (3.8–20.2)	0.926^b
Day after HSCT in days, median (range)	54 (15–331)	87 (35–296)	0.374^b
Ferritin in ng/ml, median (IQR)	2972.6	3512.7	0.913^b
Hepatomegaly, n (%)	5 (56)	6 (75)	0.147^a
Classification, n (%)
Age < 7 years, no hepatomegaly	0 (0)	0 (0)
Age > 7 years, no hepatomegaly	4 (44)	2 (25)
Age < 7 years, hepatomegaly	0 (0)	2 (25)
Age > 7 years, hepatomegaly	5 (56)	4 (50)
Conditioning regimen, n (%)
Bu + Cy		2 (22)
ATG + Flu + Bu	14 (100)	7 (78)
Chimerism, n (%)			0.412^a
Complete donor	13 (93)	9 (100)
Mixed	1* (7)
Veno-occlusive disease, n (%)	2 (14)	3 (33)	0.280^a
Graft-versus-host disease, n (%)
Acute GvHD
Grade I/II	7 (50)	2 (22)	0.171^a
Grade III/IV	0 (0)	1 (11)
Chronic GvHD	1 (7)	0 (0)	0.412^a
Infection, n (%)
Bacterial	3 (21)	0 (0)	0.136^a
Viral	7 (50)	3 (33)	0.431^a

IQR interquartile range, GvHD graft versus host disease
Conditioning regimen: ATG Thymoglobulin, Bu busulfan, Cy Cyclophosphamide, Flu fludarabine
*Donor chimerism 76.5%
*All patients in the haploidentical HSCT group received pre-transplant immunosuppression (PTIS), 7 patients who were > 7 years old in the matched-donor HSCT group received PTIS (ref. 7) PTIS consisted of fludarabine 40 mg/m²/day and dexamethasone 25 mg/m²/day
Statistical analysis performed using: ^a Chi-Square, ^b Bonferroni

ISSN: 1477-9560